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Childhood outcomes after prescription of antibiotics to 
pregnant women with preterm rupture of the membranes: 
7-year follow-up of the ORACLE I trial
S Kenyon, K Pike, D R Jones, P Brocklehurst, N Marlow, A Salt, D J Taylor 
Summary
Background The ORACLE I trial compared the use of erythromycin and/or amoxicillin–clavulanate (co-amoxiclav) 
with that of placebo for women with preterm rupture of the membranes without overt signs of clinical infection, by 
use of a factorial randomised design. The aim of the present study—the ORACLE Children Study I—was to determine 
the long-term eﬀ ects on children of these interventions.
Methods We assessed children at age 7 years born to the 4148 women who had completed the ORACLE I trial and 
who were eligible for follow-up with a structured parental questionnaire to assess the child’s health status. Functional 
impairment was deﬁ ned as the presence of any level of functional impairment (severe, moderate, or mild) derived 
from the mark III Multi-Attribute Health Status classiﬁ cation system. Educational outcomes were assessed with 
national curriculum test results for children resident in England.
Findings Outcome was determined for 3298 (75%) eligible children. There was no diﬀ erence in the proportion of 
children with any functional impairment after prescription of erythromycin, with or without co-amoxiclav, compared 
with those born to mothers who received no erythromycin (594 [38·3%] of 1551 children vs 655 [40·4%] of 1620; odds 
ratio 0·91, 95% CI 0·79–1·05) or after prescription of co-amoxiclav, with or without erythromycin, compared with 
those born to mothers who received no co-amoxiclav (645 [40·6%] of 1587 vs 604 [38·1%] of 1584; 1·11, 0·96–1·28). 
Neither antibiotic had a signiﬁ cant eﬀ ect on the overall level of behavioural diﬃ  culties experienced, on speciﬁ c 
medical conditions, or on the proportions of children achieving each level in reading, writing, or mathematics at key 
stage one. 
Interpretation The prescription of antibiotics for women with preterm rupture of the membranes seems to have little 
eﬀ ect on the health of children at 7 years of age. 
Funding UK Medical Research Council.
Introduction
The sequelae of preterm birth pose major public-health 
challenges. Children born preterm are at risk of major 
disabilities—eg, cerebral palsy—with risk increasing as 
length of gestation at birth decreases;1 many preterm 
children without disability develop important behavioural 
and educational diﬃ  culties.2,3 The prevention of preterm 
birth and reduction of associated disability are therefore 
important health priorities.
Intrauterine infection and inﬂ ammation have been asso-
ciated with an increased risk of preterm birth4 and inde-
pendently with cerebral palsy and chronic lung disease.5 
The antecedent of preterm birth which has been most 
strongly associated with infection and inﬂ ammation is 
preterm rupture of the fetal membranes (PROM). With 
conventional microbiological techniques, microbial invasion 
of the amniotic cavity has been identiﬁ ed in about 30% of 
cases of PROM;6 more sensitive PCR techniques that detect 
conserved 16s rRNA genes suggest that about 70% of births 
are found to be colonised after PROM.7
Against this background, there is unbiased evi dence 
from randomised controlled trials for anti biotic 
treatment of women with PROM. The ORACLE I trial8 
assessed the use of amoxicillin–clavulanate (co-
amoxiclav) 375 mg, or erythromycin 250 mg, or both, or 
placebo, four times daily for 10 days or until birth 
(whichever was sooner) in women presenting with 
PROM using a factorial randomised controlled trial 
design. In singleton babies born to women after PROM, 
erythromycin decreased the risk of the composite 
primary outcome (death or major cerebral abnormality 
or chronic neonatal lung disease). The prescription of 
erythromycin was also associated with prolongation of 
pregnancy and reductions in neonatal morbidity 
compared with women who did not receive 
erythromycin, and is now recommended practice.9 Co-
amoxiclav was not associated with any change in the 
primary endpoint. However, although women who 
received co-amoxiclav had prolonged pregnancy 
compared with those who did not receive any co-
amoxiclav, it was also associated with a signiﬁ cantly 
higher incidence of neonatal necrotising enterocolitis.
In this paper we report the results of the ORACLE 
Children Study I (OCS I), which provided a unique 
opportunity to determine whether the perinatal use of 
erythromycin and/or co-amoxiclav for women with 
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PROM in ORACLE I resulted in diﬀ erences in func-
tional and educational ability in childhood. 
Methods
Participants
OCS I began in 2002 and sought follow-up information 
for children at 7 years of age who were born to the 
4809 women with PROM who completed ORACLE I.8 
The study protocol has been described in detail else-
where.10 Brieﬂ y, in the original trial, women were 
informed of the intention to do a subsequent follow-up 
assessment when they gave written informed consent. 
Children were traced with the help of the UK Oﬃ  ce of 
National Statistics (ONS) and by contact with their family 
doctors (general practitioners; GPs). Details of deaths 
and families who moved out of the UK were notiﬁ ed to 
us by ONS. We did not attempt to contact the families of 
children who had been adopted, were in foster care, or 
had emigrated.
Contact details of surviving children were obtained 
from the National Health Service (NHS) National 
Strategic Tracing Service (NSTS). If no response was 
obtained to an invitation letter, the child’s GP was 
contacted to check details and possible reasons for 
non-response (eg, the child was currently in care or 
was a non-English speaker). Translations of all study 
materials were available. For those children who were 
not 7 years of age at the initial invitation, contact was 
maintained from 2001 onwards with birthday cards, 
newsletters, and change of address cards, and via a 
website.
When the child was 7 years old we conﬁ rmed their 
current address with ONS and the GP. An information 
leaﬂ et was sent to the parents, and 2 weeks later the study 
questionnaire was sent. If no response was obtained, 
contact details were checked with the GP and a reminder 
letter, including a £5 high street voucher,11 was sent by 
registered post to the parents or carers of the child during 
the week of the child’s 7th birthday. If no response was 
forthcoming, 3 weeks later, a ﬁ nal letter was sent or 
telephone contact was made.
The West Midlands Multi-centre Research and Ethics 
Committee (MREC) approved the study and the 
University of Leicester, UK, sponsored the OCS. 
Oversight was provided by an independent trial steering 
committee and data monitoring committee, both of 
which met annually. Those involved in tracing and data 
entry remained blind to the allocated treatment. All data 
to assess health and educational outcomes were double 
entered and subject to validation and logic checks. 
Data collection
Data were collected with a parent-completion postal 
questionnaire. This comprised the Health Utilities Index 
(HUI)12 from which the Multi-Attribute Health Status 
(MAHS) is derived, the Strengths and Diﬃ  culties 
Questionnaire,13 and speciﬁ c questions on respiratory 
symptoms,14 hospital admissions, convulsions, other 
speciﬁ c medical conditions, and demographic data. 
The primary outcome was deﬁ ned as the presence of 
any level of functional impairment (severe, moderate, or 
mild) derived from the mark III MAHS classiﬁ cation 
system12 within any of the individual attributes of vision, 
hearing, speech, ambulation, dexterity, emotion, cognition, 
and pain. Each attribute has either ﬁ ve or six deﬁ ned levels 
of impairment, ranging from normal function to severe 
dysfunction.15 These have been classiﬁ ed further into 
none, mild, moderate, or severe levels of severity for the 
individual attributes from the standard algorithms 
available within the HUI coding/procedure manual. The 
overall level of functional impairment was determined by 
their worst score in any attribute. Sensitivity analyses were 
also done based on the HUI3 multi-attribute utility scores 
of overall health-related quality of life,16 which became 
available after the study had begun. 
Secondary outcomes were the presence of three or 
more abnormal attributes derived from the MAHS 
classiﬁ cation system and the degree of functional 
impairment (severe, moderate, mild, none) within the 
individual domains; the number of deaths between trial 
entry and discharge and age 7 years; overall and subscale 
4809 women completed ORACLE I trial  
4148 women eligible for OCS follow-up  
4378 children 
17 women excluded
       15 protocol violations
         2 lost to follow-up
4826 women entered to ORACLE I trial 
3298 children (75%) whose outcome is known:
            3171 (72%) parents returned a questionnaire
                90 (2%) health of child known from GPs
                                  and parents
                 37 (1%) children died 
1080 children whose outcome is not known:
              55 emigrated, no contact made
            135 lost to follow-up, no contact made
              83 opted out by parents after initial contact
            807 no response to questionnaire or
                     other contact
661 women excluded
         246 women excluded due to death of child in ORACLE I trial
          376 women randomised outside the UK
             39 women withdrew before start of OCS   
Figure 1: Flowchart for PROM group through ORACLE I and extended follow-up in OCS I
*291 babies died during ORACLE I. However, only 246 women were excluded because a number had a multiple 
birth. Of the 291 babies, 225 were singletons, 42 were twins where both babies died (21 sets), and 24 were 
multiple births with live siblings.
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scores derived from the parent-completed Strengths and 
Diﬃ  culties Questionnaire; the frequency of speciﬁ c 
medical conditions including CNS problems (cerebral 
palsy, ﬁ ts/seizures, hydrocephalus with a shunt), 
respiratory problems (wheezing, medication for asthma), 
hospital admission (both in the last year and for chest 
problems), diabetes, bowel disorders, and developmental 
problems (attention deﬁ cit hyperactivity disorder derived 
from the Strengths and Diﬃ  culties Questionnaire17 or 
parent report), and other development problems.
With support from the UK Qualiﬁ cations and 
Curriculum Authority (QCA), we used results from 
national curriculum tests (key stage one), done at 7 years 
of age to assess the children’s educational attainment for 
residents in England. Such tests are not routinely done in 
other parts of the UK. Changes to the way in which the 
results of these tests are derived have occurred since 2005, 
when the assessment became teacher-based rather than 
test-based, with the results of written tests used by the 
teacher to inform the level awarded.18 
At key stage one, all children are awarded a level for each 
of reading, writing, and mathematics. These include levels 
three and four, which are above average, level two (the 
average level awarded to 60–70% of pupils, and which is 
also subdivided into three sublevels), and below level two, 
which includes children who attained level one, those who 
were working towards level one, or who were not entered 
by the teacher. For all eligible OCS I children in England, 
key stage one level data were provided anonymously by 
the UK Department for Children, Schools and Families 
(DCSF), categorised by treatment group.
Statistical analysis
The size of the study was predeﬁ ned by the number of 
women recruited to the ORACLE I trial. The indicative 
power calculation in the protocol noted that about 
4400 children were expected to be eligible for the follow-
up study. About 3·1% of the children in the any 
erythromycin group were expected to have three or more 
abnormal attributes using the MAHS scale.12 Assuming 
an 85% response rate, this gave 80% power (with 
two-tailed α=0·05) to detect a prevalence of three or more 
abnormal attributes in the no erythromycin group of 5% 
(a relative diﬀ erence between the two groups of 38%).
Erythromycin and 
co-amoxiclav
Erythromycin Co-amoxiclav Placebo
At entry to ORACLE I
Number of women 737 754 808 775
Maternal age (years) 28·8 (24·2–32·8) 28·4 (23·7–32·6) 28·8 (24·4–32·6) 28·7 (24·4–32·7)
Gestational age (days) 226 (209–238) 225 (205–237) 225 (208–238·5) 226 (205–238)
Multiple births 52 (7·1%) 56 (7·4%) 46 (5·7%) 49 (6.3%)
Maternal antibiotics in the postnatal period 180 (24·4%) 191 (25·3%) 211 (26·1%) 209 (27.0%)
Short-term outcomes of ORACLE I
Number of babies 783 807 849 822
Birth within 48 h of trial entry 270 (34·5%) 296 (36·7%) 279 (32·9%) 343 (41·7%)
Birth within 7 days of trial entry 442 (56·5%) 516 (63·9%) 498 (58·7%) 539 (65·6%)
Gestational age (days) 237 (222–249) 236 (221–247) 237 (222–248) 236 (221–247)
Birthweight (g) 2120 (1670–2585) 2092 (1611–2490) 2115 (1675–2560) 2075 (1626–2550)
Sex (male) 413 (52·7%) 422 (52·3%) 454 (53·5%) 463 (56·3%)
Admission to neonatal unit 570 (72·8%) 605 (75·0%) 623 (73·4%) 630 (76·6%)
Ventilated 147 (18·8%) 169 (20·9%) 168 (19·8%) 158 (19·2%)
Respiratory distress syndrome 154 (19·7%) 164 (20·3%) 159 (18·7%) 163 (19·8%)
Supplementary oxygen at 28 days 61 (7·8%) 69 (8·6%) 81 (9·5%) 74 (9·0%)
Positive blood culture 44 (5·6%) 39 (4·8%) 48 (5·7%) 57 (6·9%)
Necrotising enterocolitis (suspected or proven) 22 (2·8%) 13 (1·6%) 23 (2·7%) 20 (2·4%)
Abnormal cerebral ultrasonography 26 (3·3%) 26 (3·2%) 20 (2·4%) 27 (3·3%)
At entry to OCS I 
Ethnic origin (white) 710 (90·7%) 743 (92·1%) 757 (89·2%) 748 (91·0%)
Smoking in family 351 (44·8%) 364 (45·1%) 387 (45·6%) 351 (42·7%)
Damp or mould problems 47 (6·0%) 43 (5·3%) 41 (4·8%) 51 (6·2%)
Family history of asthma 354 (45·2%) 368 (45·6%) 346 (40·8%) 353 (42·9%)
Child’s age at completion of questionnaire (years) 6·97 (6·91–7·08) 6·97 (6·91–7·07) 6·94 (6·91–7·05) 6·95 (6·91–7·06)
Child’s age at the start of the academic year they 
sat key stage one tests (years)
6·46 (6·25–6·67) 6·50 (6·25–6·75) 6·50 (6·25–6·67) 6·50 (6·25–6·75)
Data are n (%) or median (IQR). 
Table 1: Characteristics of the responders in the PROM group  
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Odds ratios with 95% CI are presented for primary and 
secondary outcomes in the groups receiving co-amoxiclav 
(any co-amoxiclav: either with or without erythromycin) 
and erythromycin (any erythromycin: either with or 
without co-amoxiclav) separately. Odds ratios approximate 
relative risks when the risk is low.19 Logistic models with 
terms indicating allocation to co-amoxiclav and erythro-
mycin and an interaction term, corresponding to the 
ORACLE I trial’s factorial design, were also ﬁ tted.20 Since 
our ﬁ ndings were generally not altered when interaction 
terms were included, for simplicity they have not been 
included in models presented in the main tables, but 
they are available on the internet. Multiple births were 
treated as being independent in the analyses, but 
sensitivity analyses based on randomly selecting one 
child were also done.21
Data from the Strengths and Diﬃ  culties Questionnaire 
were classiﬁ ed as normal, borderline, or abnormal. Odds 
ratios and CI for proportions with borderline or abnormal 
scores are presented. Models with interaction terms were 
also ﬁ tted as above. 
Subgroup analyses were done as speciﬁ ed in the protocol, 
relating to multiple and singleton pregnancies, and 
gestational age subgroups used at the time of randomi-
sation (<32 weeks’ gestation and <28 weeks’ gestation). 
Relative risks and 95% CI for key stage one educational 
data were obtained from Poisson regression models, 
adjusting for test year. Because of restricted information 
available from the anonymous summary of these data 
supplied by the DCSF, sensitivity and subgroup analyses 
were not possible for these data.
Most of the outcomes presented, including the primary 
outcome of the follow-up study, can only be assessed in 
surviving children. Thus the analyses presented are not 
based on the intention-to-treat principle (ie, by analysis of 
outcomes in all those entered into the trial). However, the 
absolute risk of death was low, limiting any potential bias 
that might be introduced by undertaking the analyses of 
surviving children only, as pre-speciﬁ ed in the study proto-
col. There were no clear diﬀ erences in the numbers of 
deaths in each of the study groups at the end of ORACLE I, 
but we present sensitivity analyses using a composite death 
or any functional impairment outcome to conﬁ rm the 
limited eﬀ ect of including deaths in the analyses.
Informal allowance for the large number of comparisons 
undertaken is made in interpreting the results 
throughout.22
Outcomes for children not assessed may diﬀ er from 
outcomes for those who were assessed.23 To explore this, 
we investigated diﬀ erences between responders and non-
responders for a variety of factors: treatment group, short-
term maternal and neonatal outcomes, ethnicity, indices 
of deprivation from ONS derived from post code, and for 
those children in England, educational attainment.
Role of the funding source
The study sponsors had no involvement in the study 
design; collection, analysis, and interpretation of the 
data; in the writing of the report; and in the decision to 
submit the paper for publication. DJ and KP had full 
access to all the data. SK had ﬁ nal responsibility for the 
decision to submit for publication.
Any erythromycin 
(N=1551)
No erythromycin 
(N=1620)
OR (95% CI) Any co-amoxiclav 
(N=1587)
No co-amoxiclav 
(N=1584)
OR (95% CI)
No functional impairment 957 (61·7%) 965 (59·6%) Ref 942 (59·4%) 980 (61·9%) Ref
Any functional impairment 594 (38·3%) 655 (40·4%) 0·91 (0·79–1·05) 645 (40·6%) 604 (38·1%) 1·11 (0·96–1·28)
Mild 336 (21·7%) 382 (23·6%) 0·89 (0·75–1·05) 375 (23·6%) 343 (21·7%) 1·14 (0·96–1·35)
Moderate 173 (11·2%) 181 (11·2%) 0·96 (0·77–1·21) 175 (11·0%) 179 (11·3%) 1·02 (0·81–1·28)
Severe 85 (5·5%) 92 (5·7%) 0·93 (0·68–1·27) 95 (6·0%) 82 (5·2%) 1·21 (0·89–1·64)
Three or more abnormal 
attributes
128 (8·3%) 130 (8·0%) 1·03 (0·80–1·33) 135 (8·5%) 123 (7·8%) 1·10 (0·86–1·42) 
 Table 2: Overall level of functional impairment at age 7 years from the mark III Multi-Attribute Health Scale in children whose mothers had PROM  
Erythromycin and 
co-amoxiclav (N=763)
OR (95% CI) Erythromycin 
only (N=788)
OR (95% CI) Co-amoxiclav 
only (N=824)
OR (95% CI) Double placebo 
(N=796)
OR (95% CI)
No functional impairment 462 (60·6%) 0·98 (0·80–1·21) 495 (62·8%) 1·08 (0·88–1·33) 480 (58·3%) 0·89 (0·73–1·09) 485 (60·9%) Ref
Any functional impairment 301 (39·4%) 1·02 (0·83–1·25) 293 (37·2%) 0·92 (0·75–1·13) 344 (41·7%) 1·12 (0·92–1·36) 311 (39·1%) Ref
Mild 178 (23·3%) 1·01 (0·79–1·29) 158 (20·1%) 0·84 (0·65–1·07) 197 (23·9%) 1·08 (0·85–1·36) 185 (23·2%) Ref
Moderate 80 (10·5%) 0·98 (0·70–1·36) 93 (11·8%) 1·06 (0·77–1·46) 95 (11·5%) 1·12 (0·81–1·53) 86 (10·8%) Ref
Severe 43 (5·6%) 1·13 (0·72–1·77) 42 (5·3%) 1·03 (0·66–1·61) 52 (6·3%) 1·31 (0·85–2·02) 40 (5·0%) Ref
Three or more abnormal 
attributes
63 (8·3%) 1·15 (0·79–1·66) 65 (8·2%) 1·14 (0·79–1·65) 72 (8·7%) 1·22 (0·85–1·75) 58 (7·3%) Ref
Odds ratios are comparisons with the double placebo group.
Table 3: “Inside the table” analysis of overall level of functional impairment at age 7 years from the mark III Multi-Attribute Health Scale in children whose mothers had PROM
For more on indices of 
deprivation see http://www.
neighbourhood.statistics.gov.uk
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Results
Of the 4378 UK children eligible for follow-up, outcome 
was known for 3298 (75%). Full questionnaire data are 
available for 3171 (72%) children, data were collected from 
telephone interview or GP for 90 children (2%; included 
in the analysis of speciﬁ c medical conditions); 37 (1%) 
children had died (ﬁ gure 1). Women were unaware of 
their treatment allocation with the exception of one 
woman who requested this information before returning 
data for OCS I. Only 0·8% of data within returned 
questionnaires were missing. Full key stage one 
educational data were available for 3238 (96%) of the 3377 
English children who had been entered into the tests by 
2007. The characteristics of the responders, in each 
factorial group, were broadly similar in terms of maternal, 
demographic, and neonatal data to that of the main 
ORACLE I trial results (table 1).
Children whose outcome was unknown had younger 
mothers and experienced less neonatal morbidity 
(webtable 1), and, at least for those in England, were from 
more deprived areas than those whose outcome was 
known (webtable 2). More English children whose 
outcome was unknown scored below level two in key 
stage one tests, and were less likely to be white than were 
those whose outcome was known (webtable 2).
There was no diﬀ erence in the proportion of children 
with any functional impairment whose mothers had been 
prescribed any erythromycin, compared with those who 
received no erythromycin, or in the proportion of children 
with any functional impairment whose mothers had 
received co-amoxiclav, compared with those who received 
no co-amoxiclav (table 2). There was no evidence of an 
eﬀ ect of either antibiotic on any functional impairment 
when ﬁ tting a logistic model with terms for erythromycin, 
co-amoxiclav, and an interaction between the antibiotics 
(webtable 3); this model also showed no evidence for an 
interaction in eﬀ ects between the antibiotics (webtable 3). 
Neither antibiotic had an eﬀ ect on any functional 
impairment when missing data were assumed to 
correspond to a functional impairment (data not shown). 
Table 3 presents the results for the four treatment groups 
“inside the table” of the factorial trial;24 there were no clear 
diﬀ erences between the treatment groups. Sensitivity 
analyses based on the HUI3 multi-attribute utility 
function16 showed similar results (webtable 4). The use of 
erythromycin or of co-amoxiclav was not associated with 
any change in risk of death or of a composite endpoint of 
death or any functional impairment (table 4; webtable 5).
Neither antibiotic had a signiﬁ cant eﬀ ect on the overall 
level of behavioural diﬃ  culties experienced or the impact 
on families (table 5; webtable 6). Neither antibiotic had 
any eﬀ ect on the proportions of children failing to achieve 
each level in reading, writing, or mathematics at key 
stage one (table 6). Compared with national data, a higher 
proportion of the children surveyed here attained a score 
below level two (table 6).
There were no signiﬁ cant diﬀ erences with either anti-
biotic in the proportions of children reported as having 
Any erythromycin No erythromycin OR (95% CI) Any co-amoxiclav No co-amoxiclav OR (95% CI)
Number of women 2178 2255 2204 2229
Number of children 2323 2389 2336 2376
Stillbirths 42 (1·8%) 44 (1·8%) 0·98 (0·64–1·50) 45 (1·9%) 41 (1·7%) 1·12 (0·73–1·71)
Deaths in ﬁ rst year 107 (4·6%) 124 (5·2%) 0·88 (0·68–1·15) 113 (4·8%) 118 (5·0%) 0·97 (0·75–1·27)
Deaths after ﬁ rst year 7 (0·3%) 4 (0·2%) 1·79 (0·52–6·12) 5 (0·2%) 6 (0·3%) 0·85 (0·26–2·78)
Total deaths 156 (6·7%) 172 (7·2%) 0·93 (0·74–1·16) 163 (7·0%) 165 (6·9%) 1·01 (0·80–1·26)
Total death or any functional 
impairment
750 (32·3%) 827 (34·6%) 0·90 (0·80–1·02) 808 (34·6%) 769 (32·4%) 1·11 (0·98–1·25)
Total death or three or more 
abnormal attributes
284 (12·2%) 302 (12·6%) 0·96 (0·81–1·14) 298 (12·8%) 288 (12·1%) 1·06 (0·89–1·26)
Table 4: Deaths in ORACLE I and during OCS I in children whose mothers had PROM
Any erythromycin 
(N=1551)
No erythromycin 
(N=1620)
OR (95% CI) Any co-amoxiclav 
(N=1587)
No co-amoxiclav 
(N=1584)
OR (95% CI)
Emotional symptoms 295 (19·0%) 284 (17·5%) 1·10 (0·92–1·32) 290 (18·3%) 289 (18·2%) 1·00 (0·84–1·20)
Conduct problems 398 (25·7%) 433 (26·7%) 0·95 (0·81–1·11) 415 (26·1%) 416 (26·3%) 0·99 (0·85–1·16)
Hyperactivity 372 (24·0%) 443 (27·3%) 0·84 (0·71–0·98) 398 (25·1%) 417 (26·3%) 0·94 (0·80–1·10)
Peer problems 334 (21·5%) 343 (21·2%) 1·02 (0·86–1·21) 350 (22·1%) 327 (20·6%) 1·09 (0·92–1·29)
Prosocial behaviour 98 (6·3%) 131 (8·1%) 0·77 (0·58–1·01) 118 (7·4%) 111 (7·0%) 1·07 (0·81–1·40)
Overall (total diﬃ  culties) 310 (20·0%) 340 (21·0%) 0·94 (0·79–1·12) 329 (20·7%) 321 (20·3%) 1·03 (0·87–1·22)
Impact on family 278 (17·9%) 307 (19·0%) 0·93 (0·78–1·12) 298 (18·8%) 287 (18·1%) 1·04 (0·87–1·25)
Data are number of children scoring borderline or abnormal on each scale (%).
Table 5: Behaviour at age 7 years from the Strengths and Diﬃ  culties Questionnaire in children whose mothers had PROM
See Online for webtables 1–7
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CNS or development problems, diabetes, or total bowel 
disorders (table 7; webtable 7). There is some evidence of 
a reduction in respiratory problems in the children 
whose mothers received any erythromycin compared 
with those who received no erythromycin (table 7). 
Although there is no evidence of a signiﬁ cant increase in 
the prevalence of total bowel problems with either 
antibiotic, more children were reported to have other 
bowel problems (eg, hospital admission for constipation, 
diarrhoea, or stomach troubles, or under care of doctor 
for bowel problems) in the any co-amoxiclav group than 
in the no co-amoxiclav group (table 7). However, both of 
these results must be interpreted with caution because 
of the lack of formal adjustment for multiple 
comparisons.
Subgroup analyses for multiple/single births and for 
gestation above and below 28 and 32 weeks were pre-
planned; they generally suggest eﬀ ects consistent with 
neither antibiotic having an eﬀ ect on any functional 
impairment or on the presence of three or more 
abnormal attributes (ﬁ gure 2). Adjustment for maternal 
baseline, social class, and other factors did not 
substantially alter any of the treatment eﬀ ects seen here 
(data not shown). For further analyses, see http://www2.
le.ac.uk/Members/drj/supplementary-materials-for-
papers.
Any erythromycin 
(N=1596)
No erythromycin 
(N=1642)
RR (95% CI)* Any co-amoxiclav 
(N=1623)
No co-amoxiclav 
(N=1615)
RR (95% CI)*
Reading 360 (22·6%) 363 (22·1%) 1·03 (0·99–1·07) 354 (21·8%) 369 (22·8%) 0·98 (0·94–1·02)
Writing 418 (26·2%) 426 (25·9%) 1·01 (0·97–1·05) 405 (25·0%) 439 (27·2%) 0·98 (0·94–1·01)
Maths 257 (16·1%) 257 (15·7%) 1·01 (0·97–1·06) 250 (15·4%) 264 (16·3%) 0·99 (0·95–1·03)
Data are number of children failing to achieve level two or higher (%). Overall relative risks (RR) and 95% CI are from Poisson models for level achieved adjusting for test year, 
2002–07. National norms for 2002–07 have been standardised by the numbers of children in the OCS I cohort each year, and suggest that we would expect the following 
percentages of children to fail to achieve level two or above: reading 15%, writing 18%, maths 11%. *No evidence of overdispersion when these Poisson models are ﬁ tted.
Table 6: Educational attainment in reading, writing, and mathematics at key stage one, for England only, for children whose mothers had PROM 
Any erythromycin 
(N=1590)
No erythromycin 
(N=1671)
OR (95% CI) Any co-amoxiclav 
(N=1632)
No co-amoxiclav 
(N=1629)
OR (95% CI)
CNS problems
Cerebral palsy 46 (2·9%) 41 (2·5%) 1·18 (0·77–1·81) 39 (2·4%) 48 (2·9%) 0·81 (0·53–1·24)
Seizures 101 (6·4%) 107 (6·4%) 0·99 (0·75–1·31) 103 (6·3%) 105 (6·4%) 0·98 (0·74–1·29)
On prescribed medication 12 (0·8%) 19 (1·1%) 0·66 (0·32–1·37) 15 (0·9%) 16 (1·0%) 0·94 (0·46–1·90)
Hydrocephalus with shunt 3 (0·2%) 6 (0·4%) 0·52 (0·13–2·10) 6 (0·4%) 3 (0·2%) 2·00 (0·50–8·01)
Developmental problems
ADHD from SDQ or parental 
report
109 (6·9%) 135 (8·1%) 0·84 (0·64–1·09) 124 (7·6%) 120 (7·4%) 1·03 (0·80–1·34)
Other developmental problems 6 (0·4%) 11 (0·7%) 0·57 (0·21–1·55) 9 (0·6%) 8 (0·5%) 1·12 (0·43–2·92)
Respiratory problems
Wheezing in last year 305 (19·2%) 320 (19·2%) 1·00 (0·84–1·19) 309 (18·9%) 316 (19·4%) 0·97 (0·82–1·16)
Medication for chest problems in 
last year
286 (18·0%) 316 (18·9%) 0·94 (0·79–1·12) 298 (18·3%) 304 (18·7%) 0·97 (0·82–1·16)
Prednisolone 25 (1·6%) 46 (2·8%) 0·56 (0·35–0·92) 42 (2·6%) 29 (1·8%) 1·46 (0·90–2·35)
Oxygen 15 (0·9%) 26 (1·6%) 0·60 (0·32–1·14) 21 (1·3%) 20 (1·2%) 1·05 (0·57–1·94)
Relievers 261 (16·4%) 293 (17·5%) 0·92 (0·77–1·11) 273 (16·9%) 279 (17·1%) 0·98 (0·82–1·18)
Preventers  197 (12·4%) 219 (13·1%) 0·94 (0·76–1·15) 211 (12·9%) 205 (12·6%) 1·03 (0·84–1·27)
Hospital admission
Admission to hospital in last year 196 (12·3%) 223 (13·3%) 0·91 (0·74–1·12) 211 (12·9%) 208 (12·8%) 1·01 (0·83–1·25)
Admission for chest problems 27 (1·7%) 45 (2·7%) 0·62 (0·39–1·01) 35 (2·1%) 37 (2·3%) 0·94 (0·59–1·50)
Diabetes
Diabetes 3 (0·2%) 1 (0·1%) 3·16 (0·33–30·38) 4 (0·2%) 0 (0·0%) ··
Bowel disorders
All bowel problems 61 (3·8%) 57 (3·4%) 1·13 (0·78–1·63) 65 (4·0%) 53 (3·3%) 1·23 (0·85–1·78)
Bowel stoma 23 (1·4%) 25 (1·5%) 0·97 (0·55–1·71) 21 (1·3%) 27 (1·7%) 0·77 (0·44–1·37)
Other bowel problems 38 (2·4%) 32 (1·9%) 1·25 (0·78–2·02) 44 (2·7%) 26 (1·6%) 1·71 (1·05–2·79)
ADHD=attention deﬁ cit hyperactivity disorder. SDQ=Strengths and Diﬃ  culties Questionnaire.
Table 7: Medical conditions reported by parents of children at age 7 years whose mothers had PROM
Articles
1316 www.thelancet.com   Vol 372   October 11, 2008
Discussion
In this long-term follow-up of children whose mothers 
were entered into the ORACLE I trial of antibiotics 
prescribed for women with PROM and no overt signs of 
infection, there is no evidence of any substantial long-
term eﬀ ect in children at age 7 years associated with the 
prescription of either erythromycin or co-amoxiclav. 
Although there were some apparent diﬀ erences in a 
small number of secondary outcomes—eg, improvement 
in respiratory function with erythromycin and increased 
bowel disorders with co-amoxiclav—and despite the fact 
that these changes are biologically plausible and 
consistent with the short-term outcomes from the 
ORACLE I trial, they should be viewed with caution 
because of the large number of comparisons made.
The size of the ORACLE population made direct face-to-
face assessment of outcome impracticable and thus we 
elected to obtain proxy information about the children 
from parents. This was possible using well validated and 
standardised parent report tools, namely the Health 
Utilities Index and the Strengths and Diﬃ  culties 
Questionnaire, to assess health-related quality-of-life and 
behaviour, respectively. Although these are validated ways 
of collecting outcome data, using a questionnaire may 
mean more subtle diﬀ erences between the treatment 
groups were missed. Health conditions could only be 
assessed through parental report, which also leads to the 
potential for under reporting and some inaccuracy in 
ascertainment; in general, this might reduce the power to 
detect any associations present, since almost all the women 
in the study remained blind to their allocated treatment.
To achieve high follow-up rates using postal 
questionnaires is diﬃ  cult. We used evidence-based 
strategies to optimise the response25 and developed our 
own randomised evidence during the conduct of the 
study to maximise response.11 We maintained regular 
contact with the women originally entered into the trial, 
allowing us to achieve a high follow-up rate of 75%. 
Nonetheless, disadvantaged groups are over-represented 
in the non-responders but there was no evidence of 
diﬀ erential non-response between the randomised 
groups. Although this response rate is lower than that 
assumed in the initial power calculation, the increased 
prevalence of functional impairment resulted in power 
being increased overall. 
Cognitive impairment is the most common disability 
associated with preterm birth.26,27 School performance is 
aﬀ ected by a range of disabilities, of which general 
cognitive function is the most important, although 
additional deﬁ cits of executive function28 and attention 
may be contributory in the preterm child.2 Although we 
were unable to achieve direct cognitive assessment, we 
were able to use anonymised results from national 
curriculum tests, which allowed us to examine the 
scholastic attainment for virtually the whole population 
of surviving children in England, which we have used as 
a proxy for cognitive outcome. While the results showed 
no treatment diﬀ erences in the level of performance 
reached with either antibiotic, this group of children as 
a whole have educational attainment below national 
norms, in keeping with the excess of preterm children 
with poor academic attainment.2 Level scores are 
arguably rather weak measures of attainment; the power 
of these comparisons would have been increased by use 
of the raw scores for individual tests, but these are not 
available centrally. 
Overall
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Figure 2: Subgroup analyses for overall functional impairment for children whose mothers had PROM
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In women with PROM, positive amniotic ﬂ uid cultures 
are found in 32% of cases at the time of presentation29 
and in as many as 75% during subsequent labour.30 
Antibiotics might therefore be expected to improve 
clinical outcomes in this situation. There is also 
increasing evidence that, in addition to preterm birth, 
intrauterine infection is an independent antecedent of 
other disability, particularly cerebral palsy31 and chronic 
lung disease.32 Prescription of antibiotics for PROM 
could prevent neurological and respiratory disability by 
prolonging pregnancy or by reducing inﬂ ammation. It is 
thus disappointing that the ﬁ ndings of decreased 
neonatal morbidity after receipt of erythromycin in 
ORACLE I have not translated into long-term beneﬁ t 
detectable within the measures we used. The reasons for 
this are not clear but might be linked to the length of 
antibiotic exposure, which in this group of women was 
fairly short, since about 60% gave birth within a week.8 
There is also some evidence that antibiotic administration 
to women with PROM may neither eradicate nor prevent 
intra-amniotic infection. In a recent study of 18 women 
with intra-amniotic infection following PROM, only 
three showed no evidence of infection or inﬂ ammation 
after combination antibiotic treatment for 7–14 days and 
nine of 28 women with no evidence of intra-amniotic 
inﬂ ammation at admission developed inﬂ ammatory 
changes despite therapy; ﬁ ve of these nine women 
developed positive amniotic ﬂ uid cultures.33 This evidence 
suggests that other strategies are necessary to prevent the 
progress of infection and inﬂ ammatory changes in utero 
in the presence of ruptured membranes.
In the accompanying paper reporting the results of 
the ORACLE Children Study II34 in the presence of 
spontaneous preterm labour with intact membranes, 
we have observed an increase in the risk of any 
functional impairment with the use of erythromycin 
(with or without co-amoxiclav) and, particularly, 
increases in the numbers of children with cerebral 
palsy associated with the use of both erythromycin and 
co-amoxiclav. These results would suggest further 
caution should be used when considering the routine 
treatment of women with antibiotics where there is 
uncertainty about the diagnosis of PROM. It is clear 
that we need to better understand the role of infection 
in women with PROM and the role and wider eﬀ ects of 
antibiotics in the perinatal period. However, it is 
important to clarify that the women in ORACLE I with 
PROM were entered into the trial when there was 
clinical uncertainty about the need to prescribe 
antibiotics—ie, they showed no overt clinical signs of 
maternal or fetal infection. It is critical that women 
with evidence of clinical infection are treated with 
antibiotics, since clinical chorioamnionitis remains an 
important cause of maternal, fetal, and neonatal death. 
The results of this study should not lead to fewer 
women with overt signs of maternal or fetal infection 
receiving treatment. 
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